Pharmaceutics
Cell Therapy in Multiple Sclerosis: Clinical Advances, Limitations, and Future Perspectives from Clinical Studies-A Systematic Review.
Ola Mohamed Fathy Kamal, Doddy Denise Ojeda-Hernández, Belén Selma-Calvo, Marina García-Martín, María Teresa Larriba-González, Lucia Martin-Blanco, Jordi A Matias-Guiu, Jorge Matias-Guiu, Ulises Gomez-Pinedo
Published: 202510.3390/pharmaceutics18010030
Abstract
Background: Multiple sclerosis (MS) is a chronic autoimmune demyelinating disease of the central nervous system (CNS), characterised by inflammation, demyelination, and progressive neurodegeneration. Although current disease-modifying therapies (DMTs…
Preview only. Read the full abstract at the source